Globeflex Capital L P Has $6.78 Million Position in United Therapeutics Corporation $UTHR

Globeflex Capital L P cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 20.8% during the fourth quarter, Holdings Channel reports. The fund owned 13,917 shares of the biotechnology company’s stock after selling 3,661 shares during the quarter. United Therapeutics comprises about 1.0% of Globeflex Capital L P’s holdings, making the stock its 23rd biggest holding. Globeflex Capital L P’s holdings in United Therapeutics were worth $6,781,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $547.69 on Friday. The stock has a fifty day moving average price of $568.06 and a 200-day moving average price of $518.61. The company has a market cap of $23.25 billion, a price-to-earnings ratio of 20.22, a PEG ratio of 1.78 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.63 earnings per share. Research analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Insider Activity

In other news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $547.87, for a total transaction of $5,478,700.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,341,594.12. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 614,043 shares of company stock worth $346,186,880. 8.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on UTHR. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Royal Bank Of Canada decreased their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Cantor Fitzgerald upped their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.